pharma stocks

Covered Call on CRBP - Potential income return 9.04% in 8 days

CRBP pharma stocks
On September 10, 2020, we sold 2 covered calls on CRBP stock expiring on September 18, 2020. For this trade, we got a $43.2 premium (after commissions). Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidate This trade comes as the #14 in the month…

Update on CRBP Credit Spreads after stock falls more than 70%

CRBP pharma stocks
Corbus Pharmaceuticals (NASDAQ:CRBP) dropped more than 70% on September 8, 2020, in reaction to an unsuccessful Phase 3 clinical trial, RESOLVE-1, evaluating lead drug lenabasum in patients with a rare autoimmune disorder called diffuse cutaneous systemic sclerosis. As we are holding 2 credit spreads on CRBP stock, we decided to update our action plan. We are holding September 18 (6/5), and October 16 (5/4) expiry credit spreads Credit Spread on CRBP – 5.7% potential return in 22 days…

Credit Spread on CRBP – 8.64% potential return in 44 days

CRBP pharma stocks
On September 2, 2020, we sold a bull put credit spread on CRBP stock with options expiry set in the next 44 days. CRBP  - Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates Pharma and Biotech stocks have some juicy premiums, that's one of the…

Credit Spread on CRBP – 5.7% potential return in 22 days

CRBP pharma stocks
On August 27, 2020, we sold a bull put credit spread on CRBP stock with options expiry set in the next 30 days. CRBP  - Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates Pharma and Biotech stocks have some juicy premiums, thats one of the…

Sold 3 Naked Puts on BCRX - Potential income return 11.9% in 28 days

BCRX monthly optionspharma stocks
On August 21, 2020, we sold 3 naked puts on BCRX stock with expiry in the next 28 days (September 18) and with a strike price at $4. For these puts, we get $0.50 premium (before commissions) We call these trades naked because we are trading on margin, in case of an assignment we will borrow funds from the broker to finance the purchase.  This trade comes as the #45 in the month of August, and if we stick with our trading plan for this month, the premium generated from this trade makes us…

Credit Spread on TLRY – 2.17% potential return in 8 days

TLRY pharma stockscannabis stocks
On July 23, 2020, we sold a bull put credit spread on TLRY stock with expiry in the next 8 days. Here is our trade setup: BOT 1 TLRY JUL 31 '20 - 7 + 6 Put Bull Spread  -0.23  USD   For this trade, we got a premium of 15.2 USD (after commissions) or 2.17% potential income return in 8 days.  Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States with primary operations headquartered in Toronto, Ontario. Tilray also has operations in Australia & New…